We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals
SUPN

88 hedge funds and large institutions have $405M invested in Supernus Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

258% more call options, than puts

Call options by funds: $9.1M | Put options by funds: $2.54M

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

48% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 25

45% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 11

36% more capital invested

Capital invested by funds: $298M → $405M (+$107M)

6% more funds holding

Funds holding: 83 → 88 (+5)

Holders
88
Holders Change
+5
Holders Change %
+6.02%
% of All Funds
2.53%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.17%
New
16
Increased
37
Reduced
25
Closed
11
Calls
$9.1M
Puts
$2.54M
Net Calls
+$6.56M
Net Calls Change
+$3.23M

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$12.8M
2
MRM
Michael R. Murphy
+$10.3M
3
OHCM
Orchard Hill Capital Management
New York
+$6.85M
4
KIA
Kopp Investment Advisors
Minnesota
+$4.44M
5
NCGI
Next Century Growth Investors
Minnesota
+$4.11M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.75M
2
JGC
J. Goldman & Co
New York
-$2.74M
3
Bank of America
Bank of America
North Carolina
-$2.23M
4
MOACM
Mutual of America Capital Management
New York
-$2.18M
5
Group One Trading
Group One Trading
Illinois
-$2.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
RP
26
Reinhart Partners
Wisconsin
$1.68M +$8.91K +1,000 +0.7%
PCP
27
Perimeter Capital Partners
Georgia
$1.64M -$57K -6,396 -4%
PAM
28
Panagora Asset Management
Massachusetts
$1.6M +$65.8K +7,391 +5%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$1.54M +$492K +55,205 +65%
TCIM
30
TIAA CREF Investment Management
New York
$1.44M +$430K +48,247 +58%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$1.38M -$233K -26,157 -17%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1.37M +$418K +46,873 +60%
BC
33
Bruce & Co
Illinois
$1.09M +$891K +100,000 New
MCM
34
Moore Capital Management
New York
$1.09M +$891K +100,000 New
Jane Street
35
Jane Street
New York
$1.09M +$664K +74,537 +301%
TAM
36
Tocqueville Asset Management
New York
$1.01M -$111K -12,500 -12%
AQR Capital Management
37
AQR Capital Management
Connecticut
$999K +$812K +91,200 New
Group One Trading
38
Group One Trading
Illinois
$984K -$2.14M -239,919 -73%
BIM
39
BlackRock Investment Management
Delaware
$923K +$266K +29,831 +55%
TD Asset Management
40
TD Asset Management
Ontario, Canada
$873K -$315K -35,400 -31%
Morgan Stanley
41
Morgan Stanley
New York
$810K -$2.07M -231,903 -76%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$585K +$149K +16,700 +45%
BCM
43
Bridgeway Capital Management
Texas
$548K – – –
TA
44
Teachers Advisors
New York
$548K +$241K +27,053 +118%
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$540K – – –
Charles Schwab
46
Charles Schwab
California
$471K +$99.8K +11,200 +35%
U
47
UBS
Switzerland
$451K +$71.6K +8,039 +24%
ProShare Advisors
48
ProShare Advisors
Maryland
$436K -$23K -2,581 -6%
GIP
49
Granite Investment Partners
California
$436K +$4.8K +539 +1%
AL
50
Airain Ltd
Guernsey
$387K -$143K -16,052 -31%
1
2
3 4

SUPN Hedge Fund Activity: Q2 2014 in Review

88 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2014, worth a combined $405M — up 36% from $298M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new SUPN positions and 11 closed out — a net gain of 5 holders — while 37 added to existing stakes and 25 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $12.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $6.75M.

  • 88 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2014, up from 83 in Q1 2014.
  • Funds reported $405M of Supernus Pharmaceuticals stock for Q2 2014, up 36% quarter-over-quarter.
  • 16 funds opened new Supernus Pharmaceuticals positions in Q2 2014 and 11 closed out, a net change of +5 holders.
  • The largest Supernus Pharmaceuticals buyer in Q2 2014 was Consonance Capital Management, an estimated $12.8M added.
  • The largest Supernus Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $6.75M sold.

Based on aggregated 13F filings for Q2 2014.